Option Circle | $3,000,000 | (Mar 12, 2026)
Standard Kernel Co. | $20,000,000 | (Mar 12, 2026)
Chowbus | $81,000,000 | (Mar 12, 2026)
Evozyne
United States
- Chicago, IL
- 28/09/2023
- Series B
- $81,000,000
Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.
- Industry Biotechnology
- Website https://www.evozyne.com/
- LinkedIn https://www.linkedin.com/company/evozyne/about/
Related People
Mike GamsonFounder
United States -
Greater Chicago Area
I'm passionate about leading teams to pursue inspiring goals. I love working with intellectually curious people who can do anything, but show up everyday with humility and a drive to be better than they were yesterday. I believe that driving results matters as does taking the time in life to stop to smell the roses. I aspire to be a great colleague and I hope to be a student of new things forever.
zymtrace | $12,200,000 | (Mar 12, 2026)
AgentMail (YC S25) | $6,000,000 | (Mar 12, 2026)
Ernesta Inc. | $20,000,000 | (Mar 12, 2026)
Translucent AI | $27,000,000 | (Mar 12, 2026)
Xscape Photonics Inc | $37,000,000 | (Mar 12, 2026)
Swarm Aero | $35,000,000 | (Mar 12, 2026)
anchr | $5,800,000 | (Mar 12, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Imperium Technologies, Inc | $2,000,000 | (Mar 11, 2026)